Amid shortages of cancer drugs in the U.S., the API Innovation Center will use continuous manufacturing technology and a partnership with Apertus Pharmaceuticals and the Glioblastoma Foundation to ...

When the campus is complete, it will produce several of Lilly’s APIs and genetic medicines to serve US patients.

More than $21 billion of Lilly’s domestic manufacturing commitments this decade have been directed to Indiana.¹ The Lebanon ...

Eurofins CDMO Alphora is excited to announce the expansion of its Active Pharmaceutical Ingredient (API) manufacturing capabilities through the integration of advanced, custom-built Continuous Flow ...

Eli Lilly and Company has announced plans to invest $6.5bn in an active pharmaceutical ingredients (API) manufacturing facility at Generation Park in Houston, in the US state of Texas. The new ...

Pharmaceutical Executive: What elements is the conversation about bringing pharma manufacturing home missing? Charlie Lyon: ...